Francesco Ramirez, PhD
img_Francesco Ramirez
PROFESSOR | Pharmacological Sciences
PROFESSOR | Orthopedics
PROFESSOR | Medicine, Cardiology
Research Topics
Cardiovascular, Cell Biology, Extracellular Matrix, Genetics, Growth Factors and Receptors, Knockout Mice, Molecular Biology, Organogenesis, Skeletal Biology
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT)

Our laboratory is interested in the characterization of the multiple roles that the extracellular matrix plays during vertebrate organogenesis, and in congenital and acquired disorder of the connective tissue. We are currently focused on the characterization of pathophysiological mechanisms in Marfan syndrome and scleroderma using a combination of in vivo and ex vivo approaches. Our long-term goal is to identify suitable biological targets for therapeutic interventions against these life-threatening diseases.

Marfan syndrome is a common disorder of the connective tissue caused by mutations in fibrillin-1, the main structural component of extracellular microfibrils. We have shown that multisystem manifestations in Marfan syndrome are accounted for by the combined effects of impaired tissue integrity and promiscuous activation of TGF-B signals. We are studying the mechanisms whereby fibrillin-rich microfibrils regulate local TGF-B signals, and how dysregulation of this key function impairs morphogenesis and tissue homeostasis.

Excessive deposition of a disorganized collagen matrix resulting in loss of organ function is the hallmark of clinically distinct fibrotic conditions. Recent studies have implicated Ras stabilization by reactive oxygen species (ROS) in promoting and/or sustaining skin fibrosis in scleroderma. We are investigating the intracellular events downstream of the ROS/Ras loop leading to collagen up-regulation, as well as the functional relationship between the ROS/Ras and TGF-B signaling pathways in fibrogenesis.

For more information, please visit the Ramirez Laboratory website.

DSc, Universita degli Studi di Palermo

Postdoctoral Training, Columbia University

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Ramirez did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.